NCT07932925
The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change From Baseline in Stress Incontinence Episode Frequency (IEF)
Timeframe: Baseline, Week 52
Secondary (7)
Percent Change From Baseline in Body Weight
Percent change from baseline in Stress Incontinence Episode Frequency
Change from Baseline in Urinary Incontinence-Specific Quality of Life as assessed by the Quality-of-Life Instrument (QOL)
Change from Baseline in Fasting Lipids
Change From Baseline in weight
Show 2 moreShow less
Change From Baseline in waist circumference
Number of participants with Treatment-Emergent Adverse Event (TEAE)
Arms and interventions
Arm 1Active comparator
Participants will receive Berobenatide administered according to the study dosing regimen
Arm 2Placebo comparator
Participants will receive placebo administered according to the study dosing regimen
Drugs: Berobenatide, Placebo